Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom Pharmaceuticals highlighted 31 vonoprazan-related clinical abstracts presented at Digestive Disease Week 2026, including 28 independent analyses and three sponsored studies. The company’s sponsored analysis from the Phase 3 pHalcon-NERD-301 trial received a 'Poster of Distinction' award, recognizing its scientific merit in evaluating heartburn and regurgitation in Non-Erosive GERD patients. Independent research covered a broad range of indications, including GERD, H.
Key figures
- Independent abstracts
- 28
- Total vonoprazan abstracts
- 31
- Phathom sponsored abstracts
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.